93 related articles for article (PubMed ID: 7562433)
1. Evaluation of equations for unbound serum concentration prediction of carbamazepine and carbamazepine-10,11-epoxide in polytherapy pediatric patients with epilepsy.
Kodama Y; Kuranari M; Kodama H; Fujii I; Takeyama M
J Pharm Sci; 1995 Jul; 84(7):835-9. PubMed ID: 7562433
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of unbound serum carbamazepine and carbamazepine-10,11-epoxide concentration prediction methods in polytherapy adult patients with epilepsy.
Kodama Y; Kuranari M; Fujii I; Kodama H; Takeyama M
Am J Ther; 1996 Oct; 3(10):699-707. PubMed ID: 11862225
[TBL] [Abstract][Full Text] [Related]
3. Comparison of equations for predicting bound serum concentrations of carbamazepine and carbamazepine-10, 11-epoxide after polytherapy in patients with epilepsy.
Kodama Y; Kuranari M; Kodama H; Tsutsumi K; Fujii I; Takeyama M
J Clin Pharmacol; 1995 Oct; 35(10):995-1002. PubMed ID: 8568018
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two binding equations for prediction of the concentration of unbound valproic acid in the serum of adult epileptic polytherapy patients.
Kodama Y; Kuranari M; Kodama H; Zaizen T; Yukawa E; Fujii I; Takeyama M
J Pharm Pharmacol; 1996 Oct; 48(10):1068-72. PubMed ID: 8953510
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of binding equation method for prediction of unbound serum valproic acid concentration in pediatric patients with epilepsy.
Kodama Y; Kuranari M; Kodama H; Koike Y; Yasunaga F; Fujii I; Takeyama M
Int J Clin Pharmacol Ther; 1995 Feb; 33(2):114-8. PubMed ID: 7757310
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Binding Equation Method for Unbound Serum Concentration Prediction of Valproic Acid in Polytherapy Pediatric Patients with Epilepsy.
Kodama Y; Kuranari M; Kodama H; Ashikari Y; Fujii I; Takeyama M
Am J Ther; 1995 Feb; 2(2):106-111. PubMed ID: 11847536
[TBL] [Abstract][Full Text] [Related]
7. In vivo binding characteristics of carbamazepine and carbamazepine-10,11-epoxide to serum proteins in paediatric patients with epilepsy.
Kodama Y; Tsutsumi K; Kuranari M; Kodama H; Fujii I; Takeyama M
Eur J Clin Pharmacol; 1993; 44(3):291-3. PubMed ID: 8491247
[TBL] [Abstract][Full Text] [Related]
8. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
9. Prediction of unbound serum valproic acid concentration by using in vivo binding parameters.
Kodama Y; Kuranari M; Tsutsumi K; Kimoto H; Fujii I; Takeyama M
Ther Drug Monit; 1992 Oct; 14(5):349-53. PubMed ID: 1448839
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of carbamazepine and carbamazepine-epoxide protein binding in patients undergoing epilepsy surgery.
Gidal BE; Spencer NW; Maly MM; Pitterle ME
Epilepsia; 1996 Apr; 37(4):381-5. PubMed ID: 8603645
[TBL] [Abstract][Full Text] [Related]
11. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children.
Furlanut M; Montanari G; Bonin P; Casara GL
J Pediatr; 1985 Mar; 106(3):491-5. PubMed ID: 3973787
[TBL] [Abstract][Full Text] [Related]
12. Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population.
Falcão AC; de Almeida AM; Leitão F; Santos J; Sales F; Caramona MM
Ther Drug Monit; 1999 Apr; 21(2):224-30. PubMed ID: 10217344
[TBL] [Abstract][Full Text] [Related]
13. How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine-10,11-epoxide in serum samples?
Hermida J; Tutor JC
Ther Drug Monit; 2003 Jun; 25(3):384-8. PubMed ID: 12766569
[TBL] [Abstract][Full Text] [Related]
14. Alpha 1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11 epoxide in children with epilepsy.
Contin M; Riva R; Albani F; Perucca E; Lamontanara G; Baruzzi A
Eur J Clin Pharmacol; 1985; 29(2):211-4. PubMed ID: 4076320
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents.
Rambeck B; Sälke-Treumann A; May T; Boenigk HE
Eur Neurol; 1990; 30(2):79-83. PubMed ID: 2111243
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.
Westenberg HG; van der Kleijn E; Oei TT; de Zeeuw RA
Clin Pharmacol Ther; 1978 Mar; 23(3):320-8. PubMed ID: 627139
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase?
Svinarov DA; Pippenger CE
Ther Drug Monit; 1995 Jun; 17(3):217-20. PubMed ID: 7624916
[TBL] [Abstract][Full Text] [Related]
18. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
Steinborn B; Galas-Zgorzalewicz B
Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
[TBL] [Abstract][Full Text] [Related]
19. Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy.
Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yamaguchi T; Fujimura A
Am J Health Syst Pharm; 2002 May; 59(9):835-40. PubMed ID: 12004461
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine.
Robbins DK; Wedlund PJ; Kuhn R; Baumann RJ; Levy RH; Chang SL
Br J Clin Pharmacol; 1990 Jun; 29(6):759-62. PubMed ID: 2116161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
